Patient-oriented Research: Colon CA & Cancer Immunology

以患者为导向的研究：Colon CA

• 批准号: 7586771
• 负责人: RANDALL F HOLCOMBE
• 金额: $ 14.96万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-19 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7586771
• 关键词: Award; Biological Assay; Cancer Immunology Science; Clinical Research; Clinical Trials; Colon; Colon Carcinoma; Colorectal Cancer; Contracts; Correlative Study; Data; Dendritic Cells; Development; Diagnosis; Disease; Documentation; Event; Goals; Grapes; Hand; Hematology; Immune; Immune response; Immune system; Immunization; Immunologics; In Vitro; Inflammatory Bowel Diseases; Instruction; Interferons; Laboratories; Life Expectancy; Malignant Neoplasms; Measures; Mentors; Metastatic/Recurrent; Midcareer Investigator Award in Patient-Oriented Research; Monitor; Patients; Pilot Projects; Preventive; Research Ethics Committees; Resveratrol; Role; Signal Pathway; Skin; Therapeutic; Therapeutic Clinical Trial; Time; Translational Research; Work; Writing; base; chemotherapy; design; experience; high risk; improved; malignant stomach neoplasm; oncology; patient oriented research; peripheral blood; response; treatment strategy; tumor

This application is submitted as a competitive renewal of a midcareer investigator award in patient-oriented research (K24CA82450). The PI is Randall F. Holcombe, MD. This application details the experience, qualifications and short- and long-term patient-oriented research plans of Dr. Holcombe, as well as reviews progress during the period of support under the current award. Details about current and planned patient- oriented research is provided. These studies are focused on patient-oriented research in colon cancer and include studies related to the Wnt signaling pathway, elucidation of immunologic events in conjunction with administration of chemotherapy for colon cancer and definition of the mechanisms and potential therapeutic and cancer preventive effects of resveratrol, a naturally occuring compound found in the skin of grapes. Patients with inflammatory bowel disease, having or at high risk for colon cancer, are also studied. An additional clinical trial with laboratory correlative studies, originally designed and written by a mentee hematology-oncology fellow of Dr. Holcombe's involves the treatment of patients with gastric cancer. Mentoring activity over the past 5 years and mentoring plans for the next 5 years are described. The accomplishments of mentees are outlined as are their current activities, espeicially as related to ongoing participation in patient-oriented research. Ongoing mentoring plans include formal coursework, basic/translational research experiences, instruction in the development and implementation of clinical research trials, and hands-on experiences in clinical research. The original goals and objectives of the current award are reviewed and the extent to which these have been achieved is delineated. Documentation of institutional support and justification of the need for continued support through the K24 mechanism is provided.

该申请被作为竞争性续签，以患者为导向的中级研究员奖 研究（K24CA82450）。 PI是医学博士Randall F. Holcombe。此应用程序详细介绍了体验， 霍尔科姆博士的资格和短期和长期以患者为导向的研究计划以及评论 根据当前裁决的支持期间的进展。有关当前和计划的患者的详细信息 - 提供了定向研究。这些研究的重点是结肠癌的以患者为导向的研究和 包括与Wnt信号通路有关的研究，阐明免疫事件与 对结肠癌的化学疗法和机制的定义和潜在治疗的定义 白藜芦醇的癌症预防作用，白藜芦醇是一种自然发生在葡萄皮中的化合物。 还研究了患有或高风险结肠癌风险的炎性肠病患者。一个 额外的临床试验与实验室相关研究，最初由受训者设计和撰写 Holcombe博士的血液肿瘤学会涉及胃癌患者的治疗。 描述了过去5年中的指导活动，并描述了未来5年的指导计划。这 概述了受训者的成就以及他们当前的活动，尤其是与持续的 参与以患者为导向的研究。正在进行的指导计划包括正式课程， 基础/翻译研究经验，临床开发和实施的指导 研究试验以及临床研究的动手经验。最初的目标和目标 审查了当前奖励，并划定了这些奖项的程度。文档 通过K24机制的机构支持和对持续支持需求的理由是 假如。